The fetal liver kinase 1 (FLK-1) + hemangioblast can generate hematopoietic, endothelial, and smooth muscle cells (SMCs). ER71/ETV2, GATA2, and SCL form a core transcriptional network in hemangioblast development. Transient coexpression of these three factors during mesoderm formation stage in mouse embryonic stem cells (ESCs) robustly enhanced hemangioblast generation by activating bone morphogenetic protein (BMP) and FLK-1 signaling while inhibiting phosphatidylinositol 3-kinase, WNT signaling, and cardiac output. 
INTRODUCTION
Pluripotent stem cells provide an exciting opportunity in the field of basic as well as regenerative biology because of their unique capacity to differentiate in culture into all somatic cells that form an individual. Current efforts are aimed at generating a preferred somatic cell type by manipulating growth factors added to culture media. While these efforts have advanced the field, derivation of a homogenous specific cell population from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) still remains as a major challenge in the field. Successful derivation of a desired somatic cell lineage from ESCs or iPSCs would likely to be advanced by comprehensive understanding of how specification of that particular cell lineage is accomplished in the developing embryo. As for blood and vessel development, tracking a receptor tyrosine kinase fetal liver kinase 1 (FLK-1) expression has been instrumental. Specifically, cell lineage tracing studies have demonstrated that FLK-1 + mesoderm contributes to primitive and definitive blood, endothelial cells, and cardiac and skeletal muscles (Lugus et al., 2009; Motoike et al., 2003) .
FLK-1 + (or KDR + in human) mesoderm isolated from ESCs or embryos can generate hematopoietic, endothelial, and smooth muscle cells as well as cardiac cells (Choi et al., 1998; Faloon et al., 2000; Yamashita et al., 2000; Ema et al., 2003; Huber et al., 2004; Kennedy et al., 2007; Kattman et al., 2006; Moretti et al., 2006; Yang et al., 2008) . Importantly, hemangiogenic or cardiogenic potential of the FLK-1 + mesoderm can be segregated by the plateletderived growth factor receptor a (PDGFRa) expression in both mouse and human, such that, while the FLK-1 + PDGFRa À cell population is enriched for the hemangiogenic potential, FLK-1 + PDGFRa + cell population is enriched for the cardiogenic potential (Kattman et al., 2011; Liu et al., 2012) . Molecularly, there is an antagonistic relationship between the hemangiogenic and cardiogenic mesodermal outcome. For example, enforced Er71 expression leads to an increase in hematopoietic and endothelial cell output but a decrease in cardiac output. Conversely, Er71 deficiency results in defective hematopoietic and endothelial cell output but enhanced cardiac outcome (Lee et al., 2008; Liu et al., 2012) . Similarly, the hematopoietic program is inhibited by enforced Mesp1 or Nkx2-5 expression, which promotes cardiac differentiation (Caprioli et al., 2011; Lindsley et al., 2008) .
Herein, we reasoned that hemangioblast generation from ESCs could be enhanced by inhibiting cardiac output with defined hemangiogenic factors. We presumed that the candidate factors should be preferentially expressed within the hemangioblast population, that they could individually skew toward the hemangiogenic output, and that the skewing effect could be most dramatic when the candidate factors were coexpressed. We identify ER71, GATA2, and SCL as core factors in hemangioblast development. Transient coexpression of these three factors during mesoderm formation stage robustly enhanced FLK-1 + hemangioblast (FLK-1
production while concomitantly inhibiting cardiac outcome from differentiating ESCs. Such FLK-1 + hemangioblasts generated functional endothelial and smooth muscle cells in culture as well as in ischemic mouse hindlimbs, resulting in improved blood perfusion and limb salvage.
RESULTS

FLK-1
+ PDGFRa À Cells from ESCs Can Be Potently Generated by Temporal ER71, GATA2, and SCL Coexpression We previously reported gene expression profiling of the presumptive hemangioblasts, FLK-1 + SCL + (Chung et al., 2002; Lugus et al., 2007) . Focusing on the genes that were preferentially expressed within FLK-1 + SCL + cells or FLK-1 + cells ( Figure S1A available online), we determined if any of these could skew mesoderm toward the hemangiogenic FLK-1 + PDGFRa À outcome from ESCs. To this end, we generated A2 ESCs expressing single candidate genes in a doxycycline (DOX)-inducible manner (Ismailoglu et al., 2008) . We induced candidate genes from day 2 and analyzed FLK-1 and PDGFRa expression between days 3 and 4, mesoderm formation, and patterning stage. fide'' hemangioblasts, we subjected day 3 embryoid body (EB) cells, control and DOX-treated, to blast colony assay, an in vitro measure of hemangioblast (Choi et al., 1998) . Remarkably, DOX-treated EB cells, compared to controls, generated greatly enhanced number of blast colonies (Figure 1C) . More importantly, blast colonies were readily generated with DOX from serum-free conditions plus bone morphogenetic protein 4 (BMP-4), which normally do not support blast colony formation ( Figures 1D and  1E ). To determine if indeed all blast colonies developed from FLK-1 + cells, we sorted FLK-1 + cells from day 3 EBs, control and DOX-treated, and subjected to blast colony assay. Again, FLK-1 + PDGFRa À cells generated from DOXtreated EBs produced an increased blast colony number compared to control FLK-1 + cells ( Figure 1F ). Blast cells are capable of generating blood, endothelial, and smooth muscle cells (Choi et al., 1998; Ema et al., 2003; Yamashita et al., 2000) . To further validate that the differentiation potential of blast colonies generated from EGS-induced FLK-1 + cells
were the same as the controls, we subjected individual blast colonies to further differentiation into hematopoietic, endothelial, and smooth muscle cells. Similar percentage of blast colonies from control and DOX-treated EBs generated both hematopoietic and adherent cells ( Figure S1C ). Figure 1J and S1E). Gene expression analyses also corroborated with cell surface marker studies ( Figure 1K ). Lymphatic endothelial cell marker genes, including Prox1, Vegfr3, and Lyve1, were also highly expressed in EGS-induced FLK-1 + and differentiated progeny cells ( Figures 1B, 1J , and 1K (Figures 2A and 2B ; Schoenebeck et al., 2007) . Moreover, limiting blood and vessel specification resulted in expansion of cardiac progenitors (Schoenebeck et al., 2007) . We observed that etsrp morpholino (MO) injection alone was sufficient to convert the hemangiogenic field to cardiac, as evidenced by hand2 expression in the rostral part ( Figure 2C ), with concomitant loss of fli1a expression, a gene critical for the hemangioblast specification in zebrafish (Liu et al., 2008) . This effect was specific to the ALPM, as the lateral fli1 expression was not affected ( Figure 2K ). More importantly, etsrp-deficient embryos readily expressed hand2 in the rostral region of the ALPM ( Figure 2D ). scl MO injection also resulted in a similar extension of the cardiac field ( Figure 2E ). Although gata2 MO did not extend hand2 expression rostrally, the hand2 expression domain was expanded within the medial/lateral part ( Figure 2F ). Whereas $75% of wild-type embryos coinjected with + cells were sorted from day 3 iEGS EBs (±DOX from day 2) and analyzed for gene expression. Expression levels relative to Gapdh are shown as mean ± SD of three independent experiments. (C and F) Day 3 iEGS EBs (±DOX from day 2) were subjected to blast colony assay. Colony numbers are shown as mean ± SD of four independent experiments **p < 0.01, compared to ÀDOX. (D) iEGS ESCs were differentiated in serum-free conditions with BMP-4 (10 ng/ml) and DOX added from day 0 and day 2, respectively, and replated on day 3, 3.25, or 3.5. Blast colonies and secondary EBs were counted on day 4. Colony numbers are shown as mean ± SD of four independent experiments, **p < 0.01, compared to ÀDOX. (E) iEGS ESCs were differentiated as in (D) and analyzed for FLK-1 and PDGFRa on day 3.5. (F) FLK-1 + cells sorted from day 3 iEGS EBs (±DOX from day 2) were subjected to blast colony assay. Colony numbers are shown as mean ± SD of four independent experiments **p < 0.01, compared to ÀDOX. (G and H) Individual blast colonies were picked and cultured on type IV collagen-coated microtiter well in the presence of cytokines. Bright-field images of hematopoietic and adherent cells are shown (G), scale bar: 50 mm. After removing hematopoietic cells, adherent cells were immunostained for CD31 (red), VE-CADHERIN (red), SMAa (green), and DAPI nuclear staining (blue) (H). Scale bar: 20 mm for CD31 and VE-CADHERIN; 50 mm for SMAa. (I-K) FLK-1 + cells were sorted from day 3 iEGS EBs (±DOX from day 2), cultured on OP9 cells for 6 days, and fluorescence-activated cell sorting-analyzed for CD41, CD45, CD31, LYVE-1, and VE-CADHERIN (J) or gene expression (K). Expression levels relative to Gapdh are shown as mean ± SD of three independent experiments. (L) FLK-1 + cells were sorted as in (I), infected with GFP retrovirus, mixed in with OP9 cells and Matrigel, and injected subcutaneously into nonobese diabetic/severe combined immunodeficiency/interleukin 2 RgÀ/À mice. After 2 weeks, Matrigel plugs were excised and assessed for GFP+CD31+ or GFP+SMAa+ by immunostaining. Nuclei are shown in blue with DAPI (scale bar: 50 mm). See also Figures S1 and S2 and Table S2 .
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Enhanced Hemangioblast Generation from ESCs gata2 and scl MOs displayed the rostral extension of hand2 expression, 100% of the etsrp heterozygous (etsrp y1 1/+ ) embryos (Pham et al., 2007) , coinjected with these two MOs showed anterior enlargement of hand2 expression ( Figures  2G and 2J ). Importantly, while $80% of embryos coinjected with etsrp and scl MO resulted in rostral hand2 extension, 100% of the embryos showed conversion of the hemangiogenic field to cardiac when coinjected with all three MOs ( Figures 2H and 2I ). These results suggest the cooperativity among Er71, Scl, and Gata2 in promoting hemangiogenic mesoderm development. Collectively, simultaneous modulation of Er71, Gata2, and Scl expression in ESC or zebrafish has profound effect on the hemangiogenic outcome.
ER71, GATA2, and SCL-Mediated Genetic Program in Hemangioblast Development
The earlier and robust effect of Er71, compared to Gata2 or Scl, on the FLK-1 + PDGFRa À , skewing both in ESC and zebrafish models, suggested that ER71 functions upstream of GATA2 and SCL. Indeed, we previously reported that Er71 expression in embryos and EBs is transient (Lee et al., 2008) . The onset of Er71 expression in wild-type EBs precedes that of Gata2 and Scl expression ( Figure S3A ). Moreover, Gata2 or Scl expression in EBs was not detected in the absence of ER71 ( Figure S3A ). We also detected ER71 occupancy on the Scl promoter region ( Figure S4 ). Moreover, Er71-enforced expression resulted in robust Gata2 and Scl upregulation. On the other hand, Gata2 or Sclenforced expression failed to upregulate Er71 expression ( Figure S3B ). We conclude that ER71 establishes Gata2 and Scl expression during hemangioblast development.
To better understand genetic program-regulating hemangioblast formation, we compared global temporal gene expression changes by enforced ER71, GATA2, and Scl coexpression. Specifically, we saw an upregulation of Er71, Gata2, and Scl expression by 6 hr after DOX addition, indicating that 6 hr DOX treatment was sufficient to induce these exogenous genes. Thus, RNA from day 2.25 (6 hr after DOX addition), day 2.5 (12 hr after DOX addition), and day 3 (24 hr after DOX addition) EB cells was subjected to microarray analyses. Notably, Fli-1, Lmo2, Esam, Sox7, Sox18, Hey1, Flk-1, and Cdh5 expression was significantly upregulated within 6 hr after DOX addition, suggesting that these genes are presumably direct targets of ER71, GATA2, and Scl ( Figures 3A and 3B ). Indeed, we previously demonstrated that Flk-1 and Ve-cadherin/Cdh5 are ER71 direct targets (Lee et al., 2008; Liu et al., 2012) . Recent studies have reported that Lmo2 is also an ER71 direct target (Koyano-Nakagawa et al., 2012) . While hematopoietic and endothelial cell genes became progressively upregulated over the course of 24 hr DOX treatment, cardiac genes, including Hand1, Isl1, and Mesp1, were progressively downregulated within the same time frame (Figures 3A and 3B) . At the same time, Flk-1 expression and downstream signaling pathway genes were greatly upregulated by 24 hr after DOX addition ( Figures 3C-3E ). Cell adhesion molecules as well as Bmp-4 and Bmp-6 were also upregulated. On the other hand, BMP-4 inhibitors, including Follistatin and Cer-1 gene expression, were greatly inhibited. WNT signaling and epithelial-mesenchymal transition (EMT) pathway genes were also significantly downregulated (Figures 3C-3E ; Table S1 ). Collectively, our data suggested that enforced Er71, Gata2, and Scl coexpression resulted in activation of BMP and FLK-1 signaling and inhibition of EMT and WNT signaling.
We further performed biochemical analyses to confirm the signaling pathways identified by the global gene expression profiling. DOX treatment resulted in an increase of the total SMAD1/SMAD5/SMAD8 protein levels as well as a significant enhancement of phospho-SMAD1/ SMAD5/SMAD8, indicating that BMP signaling was indeed activated ( Figure 4A ). AKT/protein kinase B (AKT) phosphorylation was greatly reduced, but ERK phosphorylation was strongly enhanced by DOX treatment ( Figure 4A ). As total AKT or ERK protein levels remained the same, ER71, GATA2, and SCL induce hemangioblasts by selectively activating the map kinase pathway. Phopho-glycogen synthase kinase 3b (GSK3b) levels at serine 9 were greatly decreased upon DOX treatment ( Figure 4A ). The total amount of GSK3b remained the same. DOX treatment also resulted in lymphoid enhancer-binding factor-1 (LEF1) inhibition ( Figure 4A ), a key component in WNT target gene expression. Potentially, ER71-, GATA2-, and SCL-mediated WNT inhibition is achieved both by GSK3b-bCATENIN as well as LEF1 inhibition. As for EMT, Adherens/Tight 
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Enhanced Hemangioblast Generation from ESCs DOX treatment (from day 2 or 3) greatly suppressed N-CADHERIN expression ( Figure 4B ). At the same time, genes involved in EMT processes, including Snail1 and Twist1, were also suppressed by DOX addition ( Figure 4C ). CHIR99021, a GSK3b inhibitor, could partially rescue Snail1 inhibition by DOX treatment ( Figure 4D ) but not Mesp1 suppression or FLK-1 + PDGFRa + cardiac mesoderm (not shown). Notably, activation of the map kinase pathway and inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway was readily observed by enforced Er71 expression alone. SMAD1/SMAD5 activation and WNT inhibition was readily observed by enforced Gata2 and Scl expression, respectively ( Figure 4A ). This suggested that ER71, GATA2, and SCL may distinctly contribute to hemangioblast development, and the combined sum of ER71, GATA2, and SCL activity is required for the most efficient hemangioblast generation.
Since the PI3K pathway appeared to negatively regulate hemangioblast formation, we tested if we could produce FLK-1 + PDGFRa À cells even more robustly by adding PI3K
inhibitor. The percentage of FLK-1 + PDGFRa À cells generated was significantly higher when we added DOX and PI3K inhibitor together ( Figure 4E ). On the other hand, FLK-1 + PDGFRa À cells were generated less when a map kinase inhibitor was added together with DOX, indicating that the map kinase pathway positively regulates the FLK-1 + PDGFRa À cell formation ( Figure 4E ).
EGS-Induced FLK-1 + Cells Can Potently Enhance
Angiogenic Repair and Regeneration We tested if ESC-derived, EGS-induced FLK-1 + (= FLK-1 + (+DOX)) cells could be used for angiogenic repair and regeneration. Remarkably, mesenchymal stem cells (MSCs) delivered as spheroids were superior to single MSC cells in supporting vascular therapeutic activity in a mouse model of hindlimb ischemia, as they were protected from apoptosis and secreted higher levels of angiogenic factors Shim et al., 2012 S5A , and S5B). Of the conditions, the 1:5 group showed the maximal cell viability. Mitochondrial metabolic activity was also significantly higher in the (FLK-1 + (+DOX)+hMSC) spheroids (1:5 ratio) compared to others ( Figure S5C ). Previous studies have demonstrated that hMSCs readily upregulated hypoxia-inducible factor 1a (HIF-1a) in spheroids in hypoxia Shim et al., 2012) . Consistently, HIF-1a expression was readily detected in (FLK-1 + (+DOX)+hMSC) spheroids, with the expression level being the highest in spheroids containing EGSinduced FLK-1 + cells and hMSCs in a 1:5 ratio ( Figures   5C, S5D , and S5E). HIF-1a upregulation resulted in 
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Enhanced Hemangioblast Generation from ESCs enhanced human vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) gene expression, and protein production as measured by secreted protein levels. Angiogenic factor production was most robust in spheroids containing EGS-induced FLK-1 + cells and hMSCs in a 1:5 ratio ( Figures   5D, 5E , and S5F). Consequently, endothelial cells were efficiently generated in spheroids containing EGS-induced FLK-1 + cells and hMSCs in a 1:5 ratio ( Figures 5F and 5G ).
Spheroids containing only hMSCs did not express any endothelial cell genes (not shown). HIF-1a, mouse VEGF, or FGF expression was modest in spheroids generated with only EGS-induced FLK-1 + cells ( Figure 5C ; data not shown). Vitronectin and laminin gene expression was efficiently induced in all spheroids, indicating that threedimensional culture conditions augmented extracellular matrix protein production and cell-cell interactions (Figures 5H Figures 6E and 6H ). Twenty-eight days after ischemia induction, mice that received no treatment showed extensive muscle degeneration and inflammation in the ischemic region ( Figures 6I  and 6J ), resulting in a complete limb loss (95.5%; n = 22) or severe limb necrosis (4.5%; Figure 6K ). Mice that received FLK-1 + (+DOX) spheroids displayed similar muscle degeneration and limb loss (n = 5; data not shown). Mice that received hMSC spheroids did significantly better with decreased limb necrosis ( Figure 6K ). However, these mice still showed muscle degeneration and inflammation in the ischemic region ( Figures 6I and 6J ) and 27.3% of them ultimately lost limb ( Figure 6K ). Similar to mice that received hMSC spheroids, mice that received (controlFLK-1 + +hMSC) spheroids also displayed decreased limb necrosis compared to no treatment group ( Figure 6K ). However, these mice still showed muscle degeneration and inflammation in the ischemic region ( Figures 6I and 6J ) and 18.2% of them eventually lost limb ( Figure 6K ). No statistical difference was observed in fibrotic area between the two groups that received hMSC spheroids or (controlFLK-1 + +hMSC) spheroids. In contrast, mice that received (FLK-1 + (+DOX)+hMSC) spheroids were protected from limb muscle necrotic damage ( Figures 6I  and 6J ). The majority of the mice that received (FLK-1 + (+DOX)+hMSC) spheroids exhibited limb salvage (86.4%) with only mild limb necrosis (9.1%). Only 1 of the 22 mice (4.5%) lost limb ( Figure 6K ). Laser Doppler perfusion imaging analysis ( Figure 6L ) revealed that blood perfusion in ischemic limbs was significantly improved in the group that received (FLK-1 + (+DOX)+hMSC) spheroids compared to the other groups. Seven days after treatment, the relative ratios of blood flow (ischemic to normal limb) were 35.6% ± 6.0% in the (FLK-1 + (+DOX)+hMSC) spheroid-recipient group compared to the other groups (no treatment, 5.3% ± 2.2%; hMSC spheroid recipients, 13.2% ± 1.8%; controlFLK-1 + +hMSC spheroid recipients, 14.4% ± 2.8%; Figure 6L ). By day 28, (FLK-1 + (+DOX)+hMSC) spheroidtransplanted group significantly improved the relative ratio of blood perfusion (72.6% ± 6.8%) compared to the other groups (no treatment, 3.1% ± 1.7%; hMSC spheroid recipients, 44.6% ± 7.7%; controlFLK-1 + +hMSC spheroid recipients, 47.4% ± 5.1%; Figure 6L ). No statistical difference was observed between the hMSC spheroid and (controlFLK-1 + +hMSC) spheroid transplantation group.
Mice that received (FLK-1 + (+DOX)+hMSC) spheroids displayed significantly enhanced CD31 + microvessel formation compared to the other groups ( Figures 7A and 7C ). SMA-a + microvessel formation was also significantly Figure 7D ). While human VEGF, bFGF, and HGF proteins were robustly detected ( Figure 7D ), human-specific SMA-a or CD31 expression was not detected ( Figure 7C ), suggesting that the contribution of hMSCs to the vascular repair in all conditions are restricted to paracrine effects. Finally, we confirmed that EGS-induced FLK-1 + cell outcome was indeed restricted to vessel contribution in noninjury model. Specifically, we injected ESCs or (FLK-1 + (+DOX)+hMSC) spheroids subcutaneously into mice.
As expected, mice that received ESCs formed distinctive teratomas, which contained multiple tissue types, including cartilage, glands, neuroepithelium, bone, skin, and vessels ( Figures S7B and S7D ). However, mice transplanted with (FLK-1 + (+DOX)+hMSC) spheroids contained only endothelial and smooth muscle cells ( Figures S7C and S7D ).
DISCUSSION
We transiently coexpressed Er71, Gata2, and Scl during mesoderm formation stage in differentiating ESCs and greatly augmented hemangioblast generation, while nearcompletely blocking cardiac output. Similarly, we could convert hematopoietic field of the anterior lateral plate mesoderm into cardiac by inhibiting all three hemangiogenic factors in zebrafish. This implies that ER71, GATA2, and SCL form a central core network in hemangioblast development. Enforced ER71, GATA2, and SCL genetic program in ESCs resulted in activation of the BMP-4 and VEGF receptor 2 signaling pathways and inhibition of the PI3K and WNT signaling. Remarkably, each factor contributed uniquely to these signaling pathways, and the collective sum of these was essential for the final hemangioblast outcome.
From the characterizations of enforced Er71, Gata2, or Scl expression in ESCs and the three factor morphants in zebrafish, we propose that ER71 function is upstream of GATA2 and SCL and is required at the commitment stage of hemangioblast generation. GATA2 and SCL maintain the hemangioblast phenotype by suppressing the cardiac program. Indeed, ER71 alone could significantly induce hemangioblasts from ESCs. Moreover, etsrp inhibition alone was most powerful in blocking hemangiogenic outcome and converting it into cardiac field in zebrafish. In developing embryos and differentiating ESCs, Er71 expression is detected prior to Gata2 and Scl expression. Enforced Er71 expression strongly upregulated Gata2 and Scl expression within 12 hr. On the other hand, enforced Gata2 or Scl expression failed to upregulate Er71. Previous studies suggested that Gata2 and Scl are direct targets of ER71 (Kataoka et al., 2011) . We also observed ER71 occupancy on the Scl promoter region. Recent studies that only the FLK-1 + PDGFRa + cardiac mesoderm is generated from Er71-deficient ESCs (Liu et al., 2012) , that vascular endothelial and endocardial progenitors differentiate as (Katritsis et al., 2005; Lasala et al., 2010 Lasala et al., , 2012 reviewed in Critser and Yoder, 2010 and Minguell et al., 2013) . Moreover, several studies have reported that pluripotent stem-derived mature endothelial cells could improve angiogenic repair and regeneration (Cho et al., 2007; Rufaihah et al., 2011 
EXPERIMENTAL PROCEDURES
ESC Generation
Er71 +/+ and Er71 À/À ESC lines and inducible ESC lines (iEr71 and iGata2) were generated as described previously (Lee et al., 2008; Liu et al., 2012; Lugus et al., 2007) . Inducible Scl or Er71-2A-Gata2-2A-Scl (iEGS) ESCs were generated by targeting the tetresponsive locus of A2Lox cells (Ismailoglu et al., 2008) , with the construct containing the coding sequence of Scl or Er71, Gata2, and Scl, which were linked by 2A peptides (de Felipe, 2002) . Scl was fused to a Flag tag at the 3 0 end. After the correct targeting event was confirmed by a tet-responsive locus/complementary DNA vector-specific PCR, inducible Scl or Er71, Gata2, and Scl expression with 1 mg/ml DOX was verified by RNA and Immunoblot analyses.
Microarray and Pathway Enrichment Analysis
Global gene expression profiles were analyzed using the GeneChip Mouse Gene 1.0 ST arrays (Affymetrix). Data were normalized, and expression values were modeled with Partek Genomics Suite (Partek). Differentially expressed genes were determined with significant p value < 0.05 and false discovery rate < 0.25. Raw data are available at the Gene Expression Omnibus repository (accession number GSE45147). Based on the microarray data, pathway enrichment analysis and interaction networks building were performed using MetaCore Analytical Suite (GeneGo).
Mouse Hindlimb Ischemia
Hindlimb ischemia was induced in mice as previously described (Shim et al., 2012) . Four-week-old female athymic mice (20-25 g body weight; Jackson Laboratory) were anesthetized with xylazine (10 mg/kg) and ketamine (100 mg/kg). The femoral artery and its branches were ligated via skin incision using a 6-0 silk suture (Ethicon), along with the external iliac artery and all upstream arteries. The femoral artery was then excised from its proximal origin as a branch of the external iliac artery to the distal point, whereupon it bifurcates into the saphenous and popliteal arteries. All animals received humane care (Institutional Animal Care and Use Committee No. 20110260).
Transplantation of FLK-1 + (+DOX)+hMSC Spheroids into Ischemic Mouse Hindlimbs
Mice were randomly divided into five groups (n = 22 from three independent experiments). Normal mice that did not undergo any surgery or mice with surgery but without treatment were used as controls. hMSC, controlFLK-1 + +hMSC or FLK-1 + (+DOX)+hMSC spheroids (3 3 10 4 cells/spheroid; 100 spheroids/limb; total 3 3 10 6 cells/limb; 0.5 3 10 6 EGS-induced FLK-1 + cells + 2.5 3 10 6 hMSC cells/limb) were intramuscularly injected into the gracilis muscle of the medial thigh.
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Laser Doppler Imaging Analysis
Laser Doppler imaging analysis was performed as described previously (Shim et al., 2012) . A laser Doppler perfusion imager (Moor Instruments) was used for serial noninvasive physiological evaluation of neovascularization. Mice were monitored by serial scanning of surface blood flow in hindlimbs at days 0, 7, 14, 21, and 28. Digital color-coded images were scanned and analyzed to quantify a blood flow in ischemic regions from the knee joint to the toe. Mean values of perfusion were subsequently calculated. The morphological status of the ischemic limb was monitored for 4 weeks.
Statistical Analysis
The results of qRT-PCR and flow cytometry analysis were analyzed by Student's t test or one-way ANOVA (four group comparisons) with a Bonferroni multiple comparison posttest (GraphPad software). A p value <0.05 was considered significant. 
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